Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRAS | P01111 | 6/20 | 0.44 |
| ▸ | FLT3 | P36888 | 6/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27331054 | 0.94 | NRAS (0.39) | NRASFLT3 | |
| SCHEMBL27327102 | 0.94 | NRAS (0.39) | NRASFLT3 | |
| SCHEMBL30698357 | 0.89 | FLT3 (0.50) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL27332443 | 0.85 | NRAS (0.45) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL27327906 | 0.85 | NRAS (0.45) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL31639195 | 0.84 | FLT3 (0.46) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL31739545 | 0.82 | NRAS (0.48) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL27327586 | 0.82 | NRAS (0.48) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL27327754 | 0.82 | NRAS (0.48) | NRASFLT3LCKRETPDGFRB | |
| SCHEMBL27330282 | 0.82 | NRAS (0.48) | NRASFLT3LCKRETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | NRAS 371/4885FLT3 1/4885LCK 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.